Amedica® Receives Patent for Knee Prosthesis With Monoblock Silicon Nitride Ceramic Tibial Component
SALT LAKE CITY, Aug. 31 /PRNewswire/ -- Amedica Corporation, a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today that it has been granted United States Patent No. 7,776,085 B2, covering an improved knee implant prosthesis that features a monoblock ceramic tibial component for articulation with natural or prosthetic (resurfaced) femoral surfaces. This is an important addition to Amedica's substantial and growing patent portfolio concerning silicon nitride hip and knee implants.
The tibial component is created from a silicon nitride monoblock adapted for fixation relative to a patient's tibial bone. Alternately, it can be affixed by a ceramic bearing insert component carried by a tibial baseplate member that is adapted for fixation relative to the tibial bone. In either form, the monoblock silicon nitride tibial component includes one or more upwardly concave articulation surface that promotes movable bearing engagement with a generally convex or condylar-shaped femoral articulation surface.
According to Ben Shappley , Chief Executive Officer, President and Director of Amedica, the monoblock silicon nitride technology with an innovative bone-contacting Bioactive™ surface provides implants with remarkable wear characteristics and extended service life. In the long term, the technology helps surgeons achieve more successful outcomes in restoring patient function and allows individuals to return to productive and pain-free lives.
"Improvements in knee prostheses using monoblock silicon nitride with bio-ingrowth technology in the tibial component eliminate conventional polymer-based bearing inserts and the related, undesirable wear debris problems and revisions associated with the older technologies used in current implants," said Shappley. "Our unique technology allows us to combine our high-strength silicon nitride with an ultra-low wear, surface-bearing technology that is designed for secure, lifetime fixation. This gives surgeons flexibility in design choices and the ability to improve anatomic fit and function for positive, lasting results and significant outcome improvement."
Amedica, a full-line manufacturer and supplier of silicon nitride technologies that are used in spinal implant applications, has developed unique SiN materials having disruptive characteristics for spinal, hip and knee implant applications. The material is remarkably fracture resistant, and its articulating surfaces do not produce the wear debris that is linked to osteolysis-related re-operations. Additionally, the Bioactive implants provide a hydrophilic surface and a conductive cancellous structure that enhances bone ingrowth and attachment.
The company recently entered into a Joint Venture Agreement with Orthopaedic Synergies Inc., a global reconstructive hip and knee concern known for its innovative and new implant technologies, expanding its reach into a more widespread orthopaedic marketplace.
"This latest patent for expanded use of our monoblock silicon nitride technology further marks a notable milestone in orthopaedic implants and other related applications," Shappley notes. "It also further secures Amedica's future competitive position in the reconstructive implant segment, which is one of the largest and rapidly-growing segments in the industry."
Amedica Corporation is ISO 13485 certified and its products are FDA cleared and CE approved. Amedica Corporation is an emerging orthopaedic implant company focused on using its silicon nitride ceramic technologies to develop and commercialize a broad range of innovative, unique spine and total joint implants for the growing orthopaedic device market. It has brought to market various spinal implant products, while products under development include reconstructive hip and knee implants that represent a new standard of care in total joint implants based on superior performance, safety and efficacy.
SOURCE Amedica Corporation
More by this Source
Amedica Appoints Karl Farnsworth as Chief Financial Officer
Mar 11, 2013, 09:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.